Aim: To examine the role of the new grading system Prostate Cancer Risk Index (PRIX) with existing risk-grouping after high-dose-rate interstitial brachytherapy (HDR-ISBT) as monotherapy for localized prostate cancer.
Patients and Methods: We analyzed outcome in 100 patients treated by HDR-ISBT as monotherapy using PRIX and compared this with D'Amico, the National Comprehensive Cancer Network (NCCN), and Seattle classifications. The median follow-up was 74 (range=48-109) months.
Results: Five-year prostate-specific antigen control and overall survival rates were 94% and 98%, respectively. PRIX separated the risks statistically significantly (p=0.004), while D'Amico (p=0.319), NCCN 2002 (p=0.126), NCCN 2012 (p=0.052) and Seattle (p=0.112) classifications failed to show a statistically significant separation.
Conclusion: PRIX is a more useful risk classification system in high-risk patient selection than existing risk classification system in clinically localized prostate cancer after HDR-ISBT as monotherapy.
Written by:
Yoshida K, Yamazaki H, Nakamura S, Masui K, Kotsuma T, Akiyama H, Tanaka E, Yoshioka Y. Are you the author?
Department of Radiology, Osaka Medical College, Takatsuki-City, Osaka, Japan; Department of Radiology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan; Department of Radiology, National Hospital Organization, Osaka National Hospital,Osaka City, Osaka, Japan; Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Reference: Anticancer Res. 2014 Jun;34(6):3077-81.
PubMed Abstract
PMID: 24922676
UroToday.com Prostate Cancer Section
